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1. Introduction 
Hematopoiesis is the formation and development of blood cells. In a healthy adult person, 
approximately 1011–1012 new blood cells are produced daily in order to maintain steady state 
levels in the peripheral circulation. Disruption of the steady state may cause the 
development of hematological diseases, such as acute (AML) or chronic myelogenous 
leukemia (CML). All mature blood cells ultimately originate from a rare population of 
primitive pluripotent (multipotential) stem cells. The pluripotent stem cells possess self-
renewal and multi-lineage differentiation potential. The latter process leads to two major 
multipotent progenitors: myeloid progenitors and lymphoid progenitors. The myeloid 
progenitors have the ability to differentiate into mature white cells, erythrocytes, 
megakaryocytes/platelets and mast cells; whereas the lymphoid progenitors cells mainly 
produce mature T, NK, and B lymphocytes. Production of myeloid lineage cells is a highly 
complex process involving the balance between cell proliferation and differentiation, which 
is regulated by growth stimulating or inhibiting signals. Transforming Growth Factor-beta 
(TGFǃ) is a pleiotropic growth factor and is one of the major regulators of hematopoiesis 
(Fortunel NO et al. 2000). A major effect of TGFǃ on hematopoietic cells is inhibitory (Hu X 
et al 1999, Batard P et al. 2000, Ducos K et al. 2000, Fortunel NO 2000) although its 
stimulatory effect has also been observed in some types of blood cells (Keller JR 1990, 1992). 
Due to its importance in the understanding human diseases including leukemia, over past 
20 years, the mechanisms responsible for TGFǃ-induced growth inhibition or stimulation 
have been a major area of investigation and considerable insights into its action mechanisms 
have been learned. This review highlights recent progress in understanding regulatory role 
of TGFǃ and its signaling pathways in various types of cells with a focus on human myeloid 
leukemia cells.  
2. Myeloid leukemia and myelogenous leukemia cell lines 
Myeloid leukemia is a type of blood and bone marrow cancers, which includes AML and 
CML. AML is a characterized by the rapid accumulation of abnormal, immature white blood 
cells in both borrow and blood, which is caused by defects in the progenitors and/or stem cells 
population. Unlike AML, myeloid cell differentiation is preserved during the chronic phase of 
CML, a disease which originates from the presence of a genetic abnormality in stem 
cells/progenitors and the nuclei show an abnormal chromosome called the Philadelphia 
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chromosome. In a healthy person, bone marrow makes the blood stem cells and progenitors 
that mature into mature white blood cells, red blood cells and blood platelets.  
In order to simplify the study of leukemia and basic research, a number of human AML cell 
lines were established. These lines provide model systems to study the control of proliferation 
and differentiation in human myelogenous leukemia and, in a broader framework, the controls 
of normal myeloid development. More than 10 leukemic cell lines have been used in our lab to 
study Transforming Growth Factor-ǃ (TGFǃ)-mediated cell cycle control and transformed 
events, among which K562 is the first myelogenous leukemia cell line established. The cell line 
was isolated from a 53 year old female CML patient in blast crisis (Lozzio CB and Lozzio BB 
1975). K652 composed of undifferentiated blast cells that are rich in glycophorin and may be 
induced to produce fetal and embryonic hemoglobin in the presence of hemin. The rest nine 
cell lines were isolated from AML patients as described below. MV4-11 cell line was derived 
from blast cells of a 10-year-old male with biphenotypic myelomonocytic leukemia (Lange B et 
al. 1987). This cell line expresses mutated FLT3, a member of the type III receptor tyrosine 
kinase (RTK) family (Quentmeier 2003). KG-1 cell line is composed predominantly of 
myeloblasts and promyelocytes ( Koeffler HP et al. 1978). Recent studies identified a fusion of 
two genes encoding fibroblast growth factor receptors, making this cell line is a good model 
for studying gene fusion-linked leukemia (Gu TL et al. 2006). KG-1a ( Koeffler HP et al. 1980) is 
a subline isolated from KG-1. TF-1 is a growth factor-dependent human cell line that was 
originally isolated from the bone marrow cells of a patient with erythroleukemia (Kitamura T 
et al. 1989). TF-1 cells express a wide range of cytokine receptors and respond to a variety of 
cytokines. Thus, this cell line is a useful tool for studying cytokine signaling network (Rosas M 
et al 2005). TF-1a (Hu X et al. 1998) is growth factor-independent subline isolated from TF-1. A 
unique characteristic of the KG-1 and TF-1 cells is their dependence on colony-stimulating 
factor (CSF) or GM-CSF/IL-3 for proliferation, respectively, whereas KG-1a and TF-1a are 
factor-independent cell lines for their growth, although TF-1a retains its ability to respond to 
several growth factors. HL-60 is a promyelocytic cell line derived from peripheral blood 
leukocytes from a female patient with acute promyelocytic leukemia, which can be induced 
into granulocytes in the presence of DMSO (Gallagher R et al.1979). HL-60 cells differentiate 
into mononuclear phagocytes when exposed to phorbol esters (Xu YZ et al. 2011). HEL is an 
erythroleukemia cell line isolated from the bone marrow cells of a patient (Martin P and 
Papayannopoulou 1982). A mutation in Janus kinase 2 gene (JAK2) in HEL cells was identified 
in 2006 (Quentmeier H et al 2006). Mo7e (Avancd GC et al. 1988) is a subline of the M-07 
human megakaryoblastic leukemia cell line. The cells express platelet glycoprotein-2b-3a. The 
growth of Mo7e is dependent on IL-3 or GM-CSF. U937 is a cell line established from a diffuse 
histiocytic lymphoma of 37 year old male patient (Sundstrom C et al. 1976). A histocyte is a cell 
that is part of the mononuclear phagocytic system that takes part in the immune responses. 
Since U937 displays many monocytic characteristics and has thus served as a model for the 
differentiation of monocytes and macrophage in vitro (Aida J, et al. 2011). This cell line is also a 
good model for induction of apoptosis (Piedfer M et al. 2011).  
3. Effect of TGFβ on the growth of human myeloid leukemia cell lines in 
culture  
Transforming Growth Factor-ǃ (TGF) has three isoforms in mammals: TGFǃ1, TGFǃ2, and 
TGFǃ3. The ǃ1 isoform is the most abundant, universally expressed, which has been 
intensively studied. This review focuses on TGFǃ1 unless indicated otherwise. The TGFǃ-
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induced biological activities are achieved through the binding of the ligand to its cell surface 
receptor, a serine-threonine kinase complex, known as type I, II, and III (adaptor) receptors. 
TGFǃ binds to and activates the type II receptor. Then the type II receptor recruits and 
phosphorylates the type I receptor, which in turn activates Smad family proteins that carry 
signals from the receptors to the nucleus to control transcription of target genes. These gene 
products may stimulate or inhibit cell cycle progression. TGF plays an essential regulatory 
role in the control of hematopoiesis (Fortunel NO et al. 2000). First, the development of 
hematopoietic cells from mesoderm in embryos is regulated by TGFǃ signaling. Park et al 
(Park C et al. 2004) demonstrated that BMP-4, a member of TGFǃ superfamily, is able to 
induce hematopoietic differentiation from mouse embryonic stem cells. The differentiated 
cells contain all types of myeloid and lymphoid progeny (Olsen AL et al. 2006). Similar roles 
of TGFǃ in human hematopoietic stem cells have been reported (Kaufman DS  et al. 2001, 
Chadwick K et al. 2003, Cerdan C et al. 2004). Second, it has also been found that TGF is 
required for maintaining hematopoietic stem/progenitor cells in quiescent states (Batard P 
et al. 2000); in contrast, application of anti-endogenous TGF antibody induces release of 
these cells from G1 phase (Ducos K et al. 2000). In TGFǃ-/- mice, enhanced numbers of 
circulating granulocytes, monocytes, platelets, as well as colony forming units, were 
observed (Kulkarni AB et al 1993, Shull MM et al 1992). In addition, inactivation of the TGF 
signaling pathway leads to malignant transformation of early hematopoietic cells (Le 
Bousse-Kerdiles MC et al. 1996). These data indicate that TGFǃ is inhibitory to 
hematopoietic cells. However, studies from several groups suggest that the response of 
myeloid stem/progenitor cells to the inhibitory effect of TGFǃ appears to be inversely 
correlated with their maturation stage (Sing GK 1988, Keller JR 1990, Ottmann OG & Pellus 
LM 1991, Snoeck H-W 1996). Long-term repopulating stem cells, CD34+ or CD34+/CD38- 
stem/progenitor cells, early myeloid and erythroid progenitors are markedly inhibited in 
the presence of TGF, whereas more differentiated myeloid progenitors forming 
granulocyte-macrophage colonies, and late erythroid progenitors forming CFU-e are less 
inhibited or even stimulated by TGF (Keller JR 1990, 1992, 1994, Fortunel NO 2000, Ruscetti 
FW 2005, Sitnicka E 1996, McNiece IK 1992, Goey H 1989, Morita N 2003, Classen S 2007). 
The inhibitory or stimulatory role by TGFǃ in some cases seems to correlate with the 
cytokines used to promote cell growth. TGFǃ inhibits SCF-, IL-3- and CSF-1-induced colony 
formation from mouse and human hematopoietic progenitors (McNiece IK 1992, Sitnicka E 
et al 1996). In contrast, TGFǃ enhances GM-CSF-induced colony formation derived from 
normal bone marrow cells and Lin- progenitors (Keller JR 1991).  
For leukemia cells, both inhibitory and stimulatory effects have been reported (Tessier N & 
Hoang T 1988, Otten J 2011, Aglietta M 1989, Cashman JD 1992). TGF has been shown to 
inhibit the growth of clonogenic blast cells from patients with acute myeloblastic leukemia 
(AML) (Tessier N & Hoang T 1988). Mutations in the components of TGFǃ signal pathways 
may relate to the disease development (Imai Y et al. 2001). In contrast, high expression of 
ALK-1 and ALK-5, two members of TGFǃ type I receptors, was reported to be associated 
with AML (Otten J 2011). An inhibitory effect of TGFǃ was suggested by the finding of low 
levels of TGFǃ type II receptors in CML (Rooke HM 1999) and lymphoid neoplasms (Inman 
GJ et al 2000); whereas, by using TGFǃ inhibitors, Naka et al found that TGFǃ signal is 
required for maintaining Leukemia Initiating Cells (LIC) by controlling nuclear localization 
of transcription factor, FOXO, in a CML mouse model (Naka K et al. 2010).  
The data described above suggest that TGF has both negative and positive effects on the 
proliferation of normal hematopoietic and leukemia cells. However, some of the data appear 
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discordant, which may be due to the complexity of the network in vivo. In the presence of 
other growth factors, TGF-induced stimulation or inhibition could be an indirect result or 
affected by other factors. Therefore, using a cell line as a research model may provide a 
direct effect of TGFǃ and produce more consistent results. A TGF knock out hematopoietic 
cell line exhibited increased colony formation in response to IL-3, IL-6, and G-CSF (Kim S-J 
& Letterio J 2003), suggesting that TGFǃ is inhibitory to the cells. TGF has been reported to 
inhibit proliferation of mouse myeloid leukemic M1 cells and induce adherence of M1 
myeloid leukemia cells to plastic dishes (Okabe-Kado J 1989). In Josk-1 monoblastic 
leukemia cells, dephosphorylation of pRb and inhibition of c-myc were responsible for 
TGF1-induced G1 arrest (Furukawa Y 1992). In U937 cells, it identified that the inhibition 
of the cells by TGF1 was linked to low levels of transcription factors, C-jun, C-fos and Jun B 
(Kanatni Y 1996). In order to delineate the effect of TGF on more myeloid leukemia cell 
lines and to reach a general conclusion, we examined more than 10 human myeloid 
leukemia cell lines, among which MV4-11 and TF-1a are factor-independent but response 
cell lines; TF-1 and Mo7e are factor-dependent cell lines; and KG-1, KG-1a, K562, U937, 
HL60, and HEL are factor-independent and insensitive to any growth factors. We 
demonstrated that TGF is inhibitory for all these human myeloid leukemia cell lines in 
culture, with heterogeneous inhibitory responses being observed (Hu X et al 1999, Hu X & 
Zuckerman KS 2000). Inhibition of TF-1, KG-1, and K562, Mo7e, and HEL by TGFǃ has also 
been reported by other groups recently (Moller GM et al. 2007, Koutoulaki A et al 2010, 
Fukuchi Y et al 2001, Kalina U et al. 2001). Our data and some recent discoveries, clearly 
indicate that the responses of the cell lines to TGFǃ are not related to the apparent 
differentiation stages of the cells (Hu X et al 1999) but could result from differences in the 
amount of TGF receptors expressed or the degrees of the mutations (Quentmeier et al. 
2003, 2006, Gu TL et al. 2006) in TGFǃ signal components in these cells. The mechanisms by 
which TGFǃ inhibits hematopoietic cells involves in the regulation of pRb pocket proteins-
E2F complexes, downregulation of a number of cell cycle regulatory molecules, and 
upregulation of p21 (Ducos K et al 2000) and p57 (Scandura JM et al 2004) as described in 
following sections.  
4. Regulation of pRb-E2F complexes in human myeloid leukemia cells 
pRb acts as a signal transducer collecting signals from cell cycle regulatory molecules to 
transcriptional machinery. G1 protein kinases have been reported to modify pRb by 
phosphorylation, thereby promoting cell cycle progression toward DNA replication 
(Suryadinata R et al. 2011, Takaki T et al. 2004). The growth inhibition of human myeloid 
leukemia cells by TGFǃ is linked to suppression of pRb phosphorylation on multiple serine 
and threonine residues, including Ser249/Thr252, Thr373, Ser780, Ser795, and Ser807/811 
(Chen P et al. 1989, Mihara K et al. 1989, Hu X et al. 1999). Dephosphorylated pRb interacts 
with E2F transcription factors. E2F-binding sites have been found in the promoters of many 
genes that control cell cycle progression and cell proliferation, thereby E2Fs play a critical 
role in cell growth control (Iaquinta PJ et al. 2007). Previous studies identified that E2F binds 
to the pocket domain of pRB. In E2F1, the pRB-binding domain interacts with the C-
terminus of the E2F molecule. As a consequence of the pRB-E2F interaction, E2F activity is 
repressed. pRB, therefore, exerts its growth suppression function mainly through its 
sequestration of E2F activity. However, one recent report suggests that E2F-1 binding 
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affinity for pRb is not the only determinant of the E2F1 activity (Sahin F and Sladek TL 
2010a). Of the seven E2Fs well documented, E2F1, E2F2, and E2F3 are considered as 
“activator” E2Fs, whereas, E2F4, E2F5, E2F6, and E2F7 are considered to be “repressor” E2Fs 
(Attwooll C et al. 2004, Sahin F and Sladek TL 2010b). pRb and two pRb-related proteins, 
p107 and p130, show a common structure, which are collectively termed the “pocket 
proteins”. E2F1-3 bind to pRb, and E2F5 binds to p130. E2F4 can interact with the all three 
pocket proteins.  
Dephosphorylated pRb preferentially interacts with E2F1-3 (Weinberg RA et al. 1995), and 
the pRb/E2F complexes are found primarily during the G1 phase of the cell cycle (Shirodkar 
S et al. 1992, Schwarz JK et al. 1993), during which time E2F-responsive promoters are 
repressed. The dissociation of the pRb/E2F-repressor complex and liberation of free E2F 
allows for the activation of these promoters (Hiebert SW et al. 1993, Qin X-Q et al. 1995, 
Helin K et al. 1993). It was demonstrated that E2F-1 responsive gene activation was 
inhibited by overexpression of wild-type pRb, but not by a mutant pRb, whereas 
transactivation mediated by mutants of E2F1, which do not bind to pRb, was not affected by 
overexpression of wild-type pRb. Loss of E2F1-3 resulted in an acute cell cycle arrest (Wu L 
et al. 2001). It has been found that Rb gene was often mutated in patients with various 
cancers, whereas p107 and p130 genes appear to be less frequently mutated in human 
cancers, suggesting that pRb is a tumor suppressor, whereas p107 and p130 are not. 
However, recent studies from several labs have shown that p130 and p107 also actively 
involved in E2F-dependent transcription activities. For example, the major E2F complexes in 
quiescent fibroblasts were E2F4-p130. As cells enter the cell cycle, E2F4-p130 was replaced 
by E2F4-p107 and E2F4-pRb (Ikeda M et al. 1996, Moberg K et al. 1996). Subsequent 
investigators, by performing chromatin immunoprecipitation (ChIP) experiments, were able 
to locate E2F complexes in a gene promoter. They have demonstrated that in serum-
deprived cells, predominantly E2F4, p130, and a histone deacetylase (HDAC) are found to 
bind to corresponding E2F-responsive promoters (Rayman JB et al. 2002, Ren B et al. 2002, 
Takahashi Y et al. 2000). Since histones are generally hypoacetylated when a gene is turned 
off, which is regulated by HDAC, the results described above suggest that p130-E2F4 DNA 
binding activity is required for the gene inactivity and for arresting cells in quiescent state. 
As cells progress through mid-G1, E2F4 and p130 are replaced by activators E2F1, 2, and 3. 
Unexpectedly, loss of pRB had no effect on HDAC recruitment to the promoter or pRb was 
not detectable in the promoters containing the E2F responsive site in quiescent cells 
(Rayman JB et al. 2002, Takahashi Y et al. 2000). Thus, these data suggest that pRb may not 
be a primary negative regulator of E2F activity in control of cell cycle progression in these 
cells.  
As indicated in the previous section, TGF dramatically inhibits the growth of several 
human myeloid leukemia cell lines in culture with a maximal growth inhibition being 
observed in MV4-11 cells. We asked how pRb-E2F complexes were regulated in MV4-11 
cells. We found that in actively proliferating MV4-11 cells, p130 and pRb were expressed as 
peptides that migrated in multiple bands in SDS-PAGE, whereas in the cells treated with 
TGFǃ, p130 and pRb were dephosphorylated. However, TGFǃ did not dephosphrylate p107 
but inhibited expression of the molecule (Hu X et al. 2000). Subsequently, we found that 
TGFǃ-treated MV4-11 cells had very low levels of pRb-associated E2F1 and E2F3. The low 
levels of pRb-E2Fs are resulted from a low expression of E2F1 and E2F3 in response to TGF 
that arrested cells in G1 phase. Unexpectedly, proliferating cells without TGFǃ contained 
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substantial quantities of pRb-E2F1 and pRb-E2F3 complexes. In contrast, the cells treated 
with TGFǃ (i.e. G1 cells) showed increased levels of pRb-E2F4 and p130-E2F4 and low level 
of p107-E2F4, as detected by immunoprecipitation and Western blotting. Since TGFǃ 
treatment inhibited the expression p107 but not E2F4, thus, the low level of p107-E2F4 
complexes is a result of the inhibition of p107. Our data indicate that E2F4 was switched 
from p107 to pRb and p130 when p107 was inhibited in response to TGF treatment. By 
performing electrophoretic gel mobility shift assay (EMSA), we were not able to detect pRb-
E2F4 DNA binding activities either in proliferating cells or in G1 cells but exhibited the 
existence of p107-E2F4 and p130-E2F4 DNA binding complexes in G1 cells. which is 
consistent with the reports from the ChIP experiments described above. Taking together, 
our data suggest that p107 and p130, but not pRb, and the repressor E2F, but not activator 
E2Fs, play a critical role in regulating E2F-responsive gene expression in TGFǃ-mediated 
cell cycle control in human myeloid leukemia cells. This conclusion is consistent with 
several studies that have failed to detect pRb at E2F-responsive genes, whereas p107 and 
p130 are readily detectable (Aslanian A 2004, Rayman JB 2002, Takahashi Y 2000, Wells J 
2000). In addition, many cell cycle-regulated E2F targets are depressed in p107-/- and p130-
/- cells but are not depressed in Rb-/- cells (Herrera RE 1996, Hurford  Jr RK 1997, Mulligan 
GJ 1998). It is not clear if traditional activator E2Fs have any significant impact on cell cycle 
progression of MV4-11 cells, because pRb-E2F1 and pRb-E2F3 complexes have been found 
in the proliferating but not in G1 phase cells. Previous studies suggest that pRb may bind 
other regulatory regions of DNA or uses other mechanisms (Sun H et al. 2011), directly or 
indirectly, for its inhibitory function as a tumor repressor. pRb may also have both positive 
or negative role on cell growth, depending on the transcription factors it interacted (Calo E 
et al. 2010).  
5. TGFβ inhibits both G1 and G2 protein kinases in human myeloid leukemia 
cells 
In mammalian cells, the cell cycle progression is regulated by a group of cyclin dependent 
kinases (cdks) and their regulatory subunits in sequential order: cyclin D-cdk4/cdk6 and 
cyclin E-cdk2 complexes act on G1 and G1-S transition, respectively, followed by cyclin A-
cdk2 on S and cyclin B-cdc2 at G2-M transition. TGF is well known to be a negative 
regulator of G1 cyclin/cdk activity in many types of cells. This has been reported to be a 
major mechanism that is responsible for TGF-induced growth inhibition of cells. In 
epithelial and fibroblasts, the negative role of TGFǃ includes inhibition of cdk4 and 
disruption of cyclin E-cdk2 assembly (Ewen ME et al. 1993, Koff A et al 1993). Although 
TGFǃ is known to be a G1 cdk inhibitor, studies from several groups suggest potential effect 
of TGFǃ on G2 checkpoint kinase. For instance, the mouse epithelial cells treated with TGFǃ 
expressed a lower level of cdc2 as compared with the cells without TGFǃ ( Fautsch MP et al 
1995); in a hepatoma cell line, TGFǃ activates cdc2 and cdk2 followed by phosphorylation of 
pRb which in turn triggers apoptosis of the cells (Choi KS et al 1999). A new report 
published in 2008 presented evidence that disruption of Smad 3, a key component of TGFǃ-
induced signal pathway, elevated cdk 1(cdc2) activity via upregulating the expression of 
cyclin B. As a result, the uncontrolled cdk1 delayed mitotic progression (Fujita T 2008). In 
human myeloid leukemia cells, we found that inhibition of multiple cdks including cdc2 
and cdc25C is a dominant event in TGFǃ-induced growth inhibition of the cells (Hu X et al. 
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2001). Our recent studies, using TF-1 and MV4-11 human myeloid leukemia cells, 
demonstrated that TGF1-induced inhibition of leukemia cell growth is not due solely to 
downregulation of G1 cyclins and cdks but also G2 check point kinases (Hu X 2007). In MV4-
11 cells, TGF caused a rapid and transient dephosphorylation of cdc2 (Tyr15) and cdc25c 
(Ser216), with 60% and 70% inhibition of phosphorylation of the both proteins by 2-3 hours, 
respectively, followed by returning to near normal by 12 hours, and 70-100% inhibitions 
again by 24-72 hours, repectively. The dephosphorylation of cdc2 and cdc25c was followed 
by a dramatic decrease of total cdc25c (100% decrease at 48 and 72 hours) and cylcin B1 and 
cdc2 (70-90% reduction at 24 to 72 hours). Consistent with these data, cdc2 kinase activity, as 
determined by ability to phosphorylate histone H1 and GST-Rb in vitro, was markedly 
reduced in the leukemia cells treated with TGF for 24-48 h. Cyclin B1 and cdc25c were 
degraded in a ubiquitin/26S proteosome assay system in vitro, which suggests strongly that 
ubiquitination and proteasomal degradation may be the key mechanism of degradation that 
leads to block of G2-M transition. The downregulation of cdc2, cdc25c, and cyclin B1 was not 
a result of G1 arrest but a direct effect of TGFǃ, because the time required for the inhibition 
of the cells released from G2 is much shorter than the cells released from G1. Using 
immunoprecipitation and Western blotting we detected that the levels of cyclin B1-cdc2 
complexes were much lower in extracts of TGF-treated cells than in control cells. Based on 
our data, we suggest that TGFǃ suppresses growth of human myeloid leukemia cells 
through multiple pathways, by inhibiting both G1 and G2 checkpoint kinases. Since the G1 
and G2 checkpoint kinases are able to phosphorylate pRb in proliferating cells, the down 
regulation of G1 and G2 checkpoint kinases would prevent pRb phospharylation, leading to 
G1 arrest. The data also suggest that cdc2, a traditional G2 regulator in mammalian cells, 
may participate in G1 regulation. Fig. 1 illustrates diagrammatically the negative roles of 
TGFǃ in the cell cycle control in myeloid leukemic MV4-11 cells.  
 
 
Fig. 1. TGFǃ inhibits both G! and G@ cdks in MV4-11 cells 
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6. Dual roles of cdk inhibitors in human myeloid leukemia cells 
It is well known that activity of cdks is counterbalanced by cdk inhibitors (ckis). The cdk 
inhibitors can be classified into two different families: Ink4 (p16, p15, p18 and p19) and 
cip/kip (p21, p27, and p57), based on their structure similarity. Among these cdk inhibitors, 
p27 and p21 have been intensively studied in various types of cells. In quiescent cells or cells 
treated with TGFǃ show high level of p27, whereas proliferating cells or cells treated with 
mitogens express low level of p27 (Moller MB 2000). Overexpression of p27 in cultured cells 
arrests the cells in G1 phase and antisense inhibition of p27 reverses cell cycle arrest induced 
by p27 (Coats S et al 1996; Rivard N et al. 1996). In vivo, p27 is a critical regulator of cellular 
proliferation. Mice lacking p27 gene are 15–30% larger than their wild-type or hemizygous 
(p27+/−) littermates (Fero et al. 1996; Kiyokawa et al. 1996). p27 was initially thought to 
interfere with the activities of cyclin D-, E-, and A-dependent kinases. The crystal structure 
of p27 bound to cyclin-cdk2 reveals that a p27 fragment inserts itself within the cdk2 
catalytic site, blocking ATP access (Russo et al., 1996). These data lead to a popular model in 
which anti-proliferative stimuli up-regulate p27, followed by inhibition of cyclinD-cdk4, 
cyclinE-cdk2, cyclin A-cdk2 activities, and by G1 arrest/growth inhibition. Similar to p27, as 
a negative regulator of the cell cycle progression, p21 is thought to bind and inhibit 
cdk2/cyclin E and/or cdk4/cyclin D complexes, thereby arresting cells at the G1 phase. The 
induction of p21 is regulated by the tumor suppressor gene, p53, in response to DNA 
damage.  
The traditional model of p27 or p21 as a cdk inhibitor has been challenged by a number of 
studies from several labs in which p21 or p27 were demonstrated to be required for a 
cdk/cyclin kinase activity or to be a dual player in cell cycle control (Zhang H et al 1994, 
LaBaer et al 1997). It was reported that p21, at low concentration, promotes the assembly of 
active kinase complexes, whereas a high concentration of p21 causes the opposite effect in 
SAOS-2 cells derived from osteosarcoma (LaBaer et al., 1997). In an animal model, it was 
found that low concentration of p21 could promote tumor progression in the presence of 
oncogenic factors (Jones JM 1999). Primary mouse fibroblasts that are p21-/- and p27-/- 
were failed to assemble cylcin D-CDK complexes and were unable to direct cyclin D nuclear 
translocation (Cheng M 1999). Consistent with this report, p27 was demonstrated to be 
essential for mouse mammary gland morphogenesis and function (Muraoka RS et al. 2001); 
an increased level of p21 was found to be parallel with S-phase entry of oligodendrocytes 
(Bansal R et al. 2005). In another report published in the same year, p27 in mouse T cells was 
found to acts as a promoter during the early stage of the cell cycle (Rowell EA et al 2005). In 
addition, it has been reported that in MCF-7 cells, cyclin D1 promotes cellular migration 
through inducing the expression of p27 and by physically associating with p27 to promote 
cellular migration (Li Z et al. 2006). These dual roles of p21 and p27 in non-hematopoietic 
cells are consistent with what we found in human hematopoietic cells a few years ago. By 
using several human myeloid leukemia cell lines as research models, we demonstrated that 
p27 has differential effect on cdk2 and cyclin E activities, which provides supplementary 
information to the evidence of p27 and p21 having dual roles in cell cycle control described 
above (Hu X et al. 2001). Although TGFǃ greatly upregulated p27 in both cytosol and 
nucleus in MV4-11 cells, the association of p27 with cylcin E and cdk2 showed different 
patterns with increased amount of cyclin E-p27 and decreased levels of cdk2-p27 being 
detected by Western blot and immunoprecipitation. Surprised, a significant amount of p27 
was found to associate with cdk2 in proliferating cells, which was downregulated in 
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response to TGFǃ. The downregulation is a result of inhibition of total cdk2 by TGFǃ. 
However, TGF had no effect on the expression of cyclin E. By carrying out p27 
immunodepletion and transfection experiments, we further demonstrated that that at least 
some cdk2 kinase activity is associated with p27 in MV4-11cells. Additional support for this 
possibility was the observation that cells transfected with anti-sense p27 cDNA but not 
empty plasmid, downregulated cdk2 kinase activity by more than 60%. Although p27 also 
may act as an adapter of cyclin E activity, as suggested by expression of cyclin E- p27 
complexes in proliferating MV4-11 cells, p27 mainly acts as an inhibitor of cyclin E activity 
in response to TGF. This is indicated by the fact that TGF1 upregulated cyclin E-
associated p27 and was accompanied by the inhibition of cyclin E-dependent kinase activity. 
Moreover, p27 immunodepletion dramatically upregulated cyclin E-dependent kinase 
activity in TGF1 treated cells. The effect of p27 on cyclin E-dependent kinase activity is 
dose-dependent, with only high concentrations of p27 being inhibitory to cyclin E activity. 
This may explain the observation that immunodepletion of p27 or anti-sense p27 cDNA did 
not significantly increase cyclin E-dependent kinase activity in proliferating MV4-11 cells. 
These results are against the notion that p27 is a negative regulator of cdk2 kinase in vivo, at 
least in these human myeloid leukemia cells. Our data are consistent with previous findings, 
in which cell cycle arrest mediated by TGF remained intact in p27-/- cells (Nakayama et 
al., 1996) and p21 and p27 has dual roles in cell cycle control (Rowell EA et al. 2005, LaBaer 
et al. 1997, Zhang H et al. 1994). The difference is that the negative or positive role of p27 in 
our model is related to the molecules p27 interacted but not the concentrations of p27 as 
reported in the case of p21 (Matsushime et al., 1992). Taken together, we interpret our 
results to suggest that in proliferating cells p27 is associated with cdk2 and cdk4 as an 
adapter. TGF1 downregulates cdk2, cdk4, and D-type cyclins, which leaves p27kip1 free to 
bind and saturate cyclin E, inhibiting cyclin E-cdk2 assembly, rendering cyclin E-dependent 
kinase inactive. By using these two different regulatory mechanisms, TGF1 magnifies its 
cell cycle inhibitory efficiency in human myeloid leukemia cells (Hu X et al 2001).  
7. Conclusion  
New findings in recent years have provided insight into the complex roles and action 
mechanisms of TGFǃ in various types of cells. TGFǃ exhibits its distinct effect on the growth 
of human myeloid leukemia cells. Although both positive and negative roles of TGFǃ in 
hematopoiesis have been reported, the major role of TGFǃ appears to be inhibitory with 
heterogeneous responses being observed in human myeloid leukemia cells. The 
heterogeneous responses of the cells to TGFǃ are not related to the apparent differentiation 
stages of the cells but could result from differences in the expression of TGF receptors or 
degrees of the mutations in the components of TGFǃ signal pathways. TGFǃ, a traditional 
G1 cdk inhibitor, represses not only G1 but also G2 protein kinases in human myeloid 
leukemia cells. pRb has been reported to be a tumor suppressor in various types of cells. The 
new studies suggest that p130, whose gene is less mutated in cancer patients, plays a critical 
role in maintaining cells in quiescent status and in TGFǃ-mediated growth inhibition. 
Traditionally, p27 and p21 are G1 cdk inhibitors. However, new evidence suggests that p27 
and p21 have both positive and negative effect on G1 cdk activities.  
Based on the data described in this review, it is clear that TGFǃ signals have a defined role 
in regulating normal hematopoiesis, and disruption of the signaling components could lead 
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to hematologic malignancies including myeloid leukemia. These are suggested by the 
observations described above: (1) The development of hematopoietic cells from mesoderm 
in embryos is regulated by TGFǃ signaling; (2) inactivation of the TGF signaling pathway 
leads to malignant transformation of early hematopoietic cells; (3) abnormal expressions of 
the components of TGF signaling pathway have been found in AML and CML; and (4) a 
number of mutations of genes that encode TGFǃ signaling components have been detected 
in several myeloid leukemia cell lines. Thus, the mutated components may be the targets for 
therapeutic strategy of myeloid leukemia in future.  
Although new information on TGFǃ and myeloid leukemia have been emerged at an 
incredibly rapid pace, it is unclear whether some information obtained from studies 
performed in vitro mimic a physiological status in vivo. In addition, the detail about dual role 
of cdk inhibitiors and the role of pRb in leukemia transformation are also need to be 
clarified in future.  
8. References 
Aglietta, M., Stacchini, A., Severino, A., Sanavio, F., Ferrando, M.L., Piacibello, W. (1989). 
Interaction of transforming growth factor-beta with hematopoietic growth factors 
in the regulation of human normal and leukemic myelopoiesis. Exp Hematol, 17 (3): 
296-299. 
Aida J, Higuchi S, Hasegawa Y, Nagano-Ito M, Hirabayashi Y, Banba A, Shimizu T, Kikuchi 
A, Saga M, Ichikawa S (2011). Up-regulation of ceramide glucosyltransferase 
during the differentiation of U937 cells. J Biochem. May 10. (ahead of print) 
Aslanian A, Iaquinta PJ, Verona R, Lees JA (2004). Repression of the Arf tumor suppressor 
by E2F3 is required for normal cell cycle kinetics. Genes Dev. 18 (12):1413-22. 
Attwooll, C., Denchi, E.L., Helin, K. (2004). The E2F family: specific functions and overlapping 
interests. EMBO J, 23 (24):  4709-4716.  
Avancd GC, Lista P, Giovinazzo B, Miniero R, Saglio G, Benetton G, Coda R, Catoretti G and 
Pegoraro P. (1988). Selective growth response to IL-3 of a human leukemic cell line 
with megakaryoblastic features. Br J Haematol 69 (3): 359-366.  
Bansal R, Marin-Husstege M, Bryant M, Casaccia-Bonnefil P. (2005). S-phase entry of 
oligodendrocyte lineage cells is associated with increased levels of p21Cip1. 
Neurosci Res. May 1; 80(3):360-368. 
Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T Hatzfeld A, 
Hatzfeld JA. (2000). TGF-b1 maintains hematopoietic immaturity by a reversible 
negative control of cell cycle and induces CD34 antigen up-modulation. J Cell Sci 
113: (Pt 3) 383–390.  
Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA (2010). Rb 
regulates fate choice and lineage commitment in vivo. Nature. Aug 26; 466 
(7310):1110-1114.  
Cashman, J.D., Eaves, A.C., Eaves, C.J. (1992). Granulocyte-macrophage colony-stimulating 
factor modulation of the inhibitory effect of transforming growth factor-beta on 
normal and leukemic human hematopoietic progenitor cells. Leukemia, Sep, 6 (9): 
886-892. 
Cerdan C, Rouleau A, Bhatia M. (2004) VEGF-A165 augments erythropoietic development 
from human embryonic stem cells. Blood 2004; April 1, 103(7):2504-2512.  
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
207 
Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A, Bhatia M (2003) Cytokines 
and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. 
Blood, August 1, 102(3):906-915.  
Chen, P., Scully, P.J., Shew, Y., Wang, J.Y., Lee, W.H. (1989). Phosphorylation of the 
retinoblastoma gene product is modulated during the cell cycle and cellula 
differentiation. Cell, Sep 22, 58 (6): 1193-1198.  
Cheng, M., Olivier, P., Diehl, J.A., Fero, M., Roussel, M.F., Roberts, J.M., Sherr, C.J. (1999). The 
p21cip1 and p27kip1 `inhibitors' are essential activators of cyclin D-dependent kinases in 
murine fibroblasts. EMBO J, March 15, 18(6): 1571-1583.  
Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, Yoon JW, Kim SJ. (1999) Cdc2 and Cdk2 kinase 
activated by transforming growth factor-beta1 trigger apoptosis through the 
phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem. Nov 
5, 274(45):31775-83.  
Classen, S., Zander, T., Eggle, D., Chemnitz, J.M., Brors, B., Büchmann, I., Popov, A., Beyer, 
M., Eils, R., Debey, S., Schultze, J.L. (2007). Human resting CD4+ T cells are 
constitutively inhibited by TGF beta under steady-state conditions. J Immunol, Jun 
1, 178(11): 6931-6940.  
Coats S, Flanagan WM, Nourse J, Roberts JM. (1996) Requirement of p27Kip1 for restriction 
point control of the fibroblast cell cycle. Science, May 10, 272(5263):877-880.  
Ducos K, Panterne B, Fortunel N, Hatzfeld A, Monier MN, Hatzfeld J. (2000) p21(cip1) 
mRNA is controlled by endogenous transforming growth factor-b1 in quiescent 
human hematopoietic stem/progenitor cells. J Cell Physiol July, 184 (1): 80–85. 
Ewen ME, Sluss HK, Whitehouse LL, Livingston DM (1993). TGF beta inhibition of cdk4 
synthesis is linked to cell cycle arrest. Cell, Sep 24, 74 (6):1009-1020.  
Fautsch MP, Eblen ST, Anders RA, Burnette RJ, Leof EB (1995). Differential regulation of 
p34cdc2 and p33cdk2 by transforming growth factor-beta 1 in murine mammary 
epithelial cells. J Cell Biochem August, 58 (4):517-526.  
Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy 
V., Perlmutter R.M. (1996). A syndrome of multiorgan hyperplasia with features of 
gigantism, tumorigenesis, and female in p27(Kip1)-deficient mice. Cell, May 31 85 
(5) :733–744  
Fortunel NO, Hatzfeld A, Hatzfeld JA. (2000). Transforming growth factor-b: pleiotropic 
role in the regulation of hematopoiesis. Blood Sep 15, 96(6): 2022–2036.  
Fujita T, Epperly MW, Zou H, Greenberger JS, Wan Y. (2008) Regulation of the anaphase-
promoting complex-separase cascade by transforming growth factor-beta 
modulates mitotic progression in bone marrow stromal cells. Mol Biol Cell, Dec., 
19(12):5446-55. 
Fukuchi Y, Kizaki M, Yamato K, Kawamura C, Umezawa A, Hata Ji, Nishihara T, Ikeda Y. 
(2001) Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis 
and differentiation of CML cells. Oncogene, Feb 8, 20(6):704-713.  
Furukawa, Y., Uenoyama, S., Ohta, M., Tsunoda, A., Griffin, J.D., Saito, M. (1992). 
Transforming growth factor-ǃ inhibits phosphorylation of the retinoblastoma 
susceptibility gene product in human monocytic leukemia cell line JOSK-I. J Bio 
Chem, August 25, 267(24), 17121-17127. 
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
208 
Gallagher R, Collins S, Trujillo J, et al. (1979). Characterization of the continuous, 
differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic 
leukemia. Blood, Sep., 54 (3): 713–733.  
Goey, H., Keller, J.R., Back, T., Longo, D.L., Ruscetti, F.W., Wiltrout, R.H. (1989). Inhibition 
of early murine hematopoietic progenitor cell proliferation after in vivo 
localregional administration of transforming growth factor-1. J Immunol, August 1, 
143(3), 877-880.  
Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, Walters DK, Wang Y, Rush J, 
Comb MJ, Druker BJ, Polakiewicz RD. (2006). Phosphotyrosine profiling identifies 
the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid 
leukemia. Blood, Dec 15, 108(13):4202-4204.  
Helin, K., Harlow, E., and Fattaey, A. (1993). Inhibtion of E2F-1 transactivation by direct 
binding of the retinoblastoma gene. Mol cell Biol, Oct, 13(10): 6501-6508.  
Herrera, R.E., Sah, V.P., Williams, B.O., Makela, T.P., Weinberg, R.A., Jacks, T. (1996). Altered 
cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-
deficient fibroblasts. Mol. Cell Biol, May, 16(5), 2402-2407.  
Hiebert, S.W. (1993). Regions of the retinoblastoma gene product required for its interaction with the 
E2F transcription factor are necessary for E2F promoter repression and pRb-mediated 
growth suppression. Mol Cell Biol, Jun, 13(6): 3384-3391.  
Hu, X., Cress, D.W., Zhong, Q., Zuckerman, K.S. (2000). Phosphorylation of pRB family and 
formation of pRb family/E2F-4 complexes are differentially regulated in 
proliferating cells and cells arrested in G1-phase by TGF1. Biochem Biophys Res 
Commun, Oct, 276(3): 930-939.  
Hu X, Cui D, Moscinski LC, Zhang X, Maccachero V, Zuckerman KS. (2007) TGFbeta 
regulates the expression and activities of G2 checkpoint kinases in human myeloid 
leukemia cells. Cytokine, Feb, 37(2):155-162.  
Hu X, Moscinski LC, Hill BJ, Fisher AB, and Zuckerman KS. (1998). Characterization of a 
unique factor-independent variant derived from human factor-dependent TF-1 
cells: a transformed event. Leukemia Res Sep, 22(9): 817-826 
Hu, X., Moscinski, L.C., Zuckerman, K.S. (1999). Transforming growth factor- (TGF) 
inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma 
protein phosphorylation at Ser795. Exp Hematol, Apr, 27(4), 605-614. 
Hu, X., Zhang, X., Zhong, Q., Fisher, A.B., Bryington, M., Zuckerman. K.S. (2001). 
Differential effects of transforming growth factor on cell cycle regulatory molecules 
in human myeloid leukemia cells. Oncogene, Oct 18, 20(47): 6840-6850.  
Hu X Zuckerman KS (2000) Cell cycle and transcriptional control of human myeloid 
leukemic cells by transforming growth factor beta. Leukemia and Lymphoma Jul, 
38(3-4): 235-246. 
Hurford, R.K. Jr., Cobrinik, D., Lee, M.H., Dyson, N. (1997). pRB and p107/p130 are 
required for the regulated expression of different sets of E2F responsive genes. 
Genes Dev, Jun 1, 11(11): 1447-1463. 
Iaquinta PJ, Lees JA. (2007). Life and death decisions by the E2F transcription factors. Curr 
Opin Cell Biol. Dec, 19(6):649–657. 
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
209 
Ikeda, M.A., Jakoi, L., Nevins, J.R. (1996). A unique role for the Rb protein in controlling E2F 
accumulation during cell growth and differentiation. Proc Natl Acad Sci U S A, Apr 
16, 93(8): 3215-3220. 
Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. 
(2001). Mutations of the Smad4 gene in acute myelogeneous leukemia and their 
functional implications in leukemogenesis. Oncogene. Jan 4, 20(1): 88-96. 
Inman GJ, Allday MJ. (2000). Resistance to TGF-ǃ1 correlates with a reduction of TGF-ǃ type 
II receptor expression in Burkitt’s pymphoma and Epsein-Barr virus-transformed B 
lymphoblastoid cell lines. J Gen Virol,  Jun, 81(Pt 6): 1567-1578. 
Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. 
(2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-
beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, 
and ALK7. Mol Pharmacol. Jul, 62(1): 65-74.  
Jones JM, Cui XS, Medina D, Donehower LA. (1999). Heterozygosity of p21WAF1/CIP1 
enhances tumor cell proliferation and cyclin D1-associated kinase activity in a 
murine mammary cancer model. Cell Growth Differ, Apr,10(4):213-222.  
Kanatni, Y., Kasukabe, T., Okabe-Kado, J., Hayashi, S.I., Yamamoto-Yamaguchi, Y., 
Motoyoshi, K., Nagata, N., Honma, Y. (1996). Transforming growth factor beta and 
dexamethasone cooperatively enhance c-jun gene expression and inhibit the 
growth of human monocytoid leukemia cells. Cell Growth & Differ, Feb, 7(2): 187-
196.  
Kalina U, Koschmieder S, Hofmann WK, Wagner S, Kauschat D, Hoelzer D, Ottmann OG. 
Transforming growth factor-beta1 interferes with thrombopoietin-induced signal 
transduction in megakaryoblastic and erythroleukemic cells.(2001). Exp Hematol 
May, 29(5): 602-608. 
Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-
forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 
2001, Sep 11, 98(19):10716-10721. 
Keller, J.R., Bartelmez, S.H., Sitnicka, E.,  Ruscetti, F.W., Ortiz, M., Gooya, J.M.,  Jacobsen, 
S.E.W. (1994). Distinct and overlapping direct effects of macrophage inflammatory 
protein-1 alpha and transforming growth factor beta on hematopoietic 
progenitor/stem cell growth. Blood, Oct 1, 84(7), 2175-2181. 
Keller, J.R., Jacobsen, S.E.W., Dubois, C.M., Hestda, I.K., Ruscetti, F.W. (1992). Transforming 
growth factor-beta: A bidirectional regulator of hematopoietic cell growth. Int. J Cell 
Cloning, Jan, 10(1):2-11. 
Keller, J.R., Jacobsen, S.E.W., Sill, K., Ellingsworth, L., Ruscetti, F.W. (1991). Stimulation of 
granulopoiesis by transforming growth factor ǃ: Synergy with granulocyte-
macrophage colony-stimulating factor. Proc Natl Acad Sci USA,  Aug 15, 88(16): 
7190-7194 
Keller, J.R., McNiece, I.M., Sill, K.T., Ellingsworth, L.R., Quesenberry, P.J., Sing, G.K., 
Ruscetti, F.W. (1990). Transforming growth factor-ǃ directly regulates primitive 
murine hematopoietic cell proliferation. Blood, Feb 1, 75(3): 596-602.  
Kim SJ, Letterio J. (2003). Transforming growth factor-ǃ signaling in normal and malignant 
hematopoiesis. Leukemia, Sep, 17(9): 1731-1737.  
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
210 
Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao Y-F, Miyazonno K, 
Urabe A and Takaku F. (1989). Establishment and characterization of a unique 
human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J 
Cell Physiol Aug, 140(2): 323-334. 
Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., 
Khanam D., Hayday A.C., Frohman L.A., Koff A (1996). Enhanced growth of mice 
lacking the cyclin-dependent kinase inhibitor function of p27(Kip1) Cell. May 31, 
85(5):721–732 
Koeffler HP, Billing R, Lusis AJ, Sparkes R and Golde DW. (1980). An undifferentiated 
variant derived from the human acute myelogenous leukemia cell line (KG-1). 
Blood Aug, 56(2): 265-273 
Koeffler HP and Golde DW. (1978). Acute myelogenous leukemia: a human cell line 
responsive to colony-stimulating activity. Science, Jun 9, 200(4346): 1153-1154 
Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J (1993). Negative regulation of G1 in 
mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science Apr 
23, 260(5107): 536-539.  
Koutoulaki A, Langley M, Sloan AJ, Aeschlimann D, Wei XQ. (2010). TNFalpha and TGF-
beta1 influence IL-18-induced IFNgamma production through regulation of IL-18 
receptor and T-bet expression. Cytokine, Feb, 49(2):177-184. 
Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC et al (1993). Transforming 
growth factor beta 1 null mutation in mice causes excessive inflammatory response 
and early death. Proc Natl Acad Sci USA, Jan 15,  90(2): 770–774. 
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, 
Harlow E. (1997). New functional activities for the p21 family of CDK inhibitors. 
Genes Dev,  Apr 1, 11(7):847-862. 
Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, 
Finan J, Nowell P,  Rovera G. (1987). Growth factor requirements of childhood 
acute leukemia: establishment of GM-CSF-dependent cell lines. Blood, Jul, 70 (1): 
192-199. 
Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, 
Praloran V, Dupriez B, Demory JL, Jasmin C, Martyré MC. (1996). Differential 
expression of transforming growth factor-b, basic fibroblast growth factor, and 
their receptors in CD34+ hematopoietic progenitor cells from patients with 
myelofibrosis and myeloid metaplasia. Blood. Dec 15, 88(12):4534-4546. 
Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti MP, Katiyar S, Pestell RG. (2006). Cyclin D1 
induction of cellular migration requires p27(KIP1). Cancer Res,  Oct 15, 66(20):9986-
94.  
Lozzio, C.B. Lozzio, B.B. (1975), "Human chronic myelogenous leukemia cell-line with 
positive Philadelphia chromosome", Blood Mar, 45(3): 321–334,  
Martin P and Papayannopoulou T. (1982). HEL cells: a new human erythroleukemia cell line 
with spontaneous and induced globin expression. Science, Jun 11, 216(4551): 1233-
1235. 
McNiece, I.K., Bertoncello, I., Keller, J.R., Ruscetti, F.W., Hartley, C.A., Zsebo, K.M. (1992). 
Transforming growth factor  inhibits the action of stem cell factor on mouse and 
human hematopoietic progenitors. Int. J. Cell Cloning, Mar, 10(2), 80-86. 
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
211 
Mihara, K., X.R. Cao, A. Yen, S. Chandler, B. Driscoll, AL. Murphree, A. Tang, and YK Fung. 
(1989). Cell cycle-dependent regulation of phosphorylation of the human 
retinoblastoma gene product. Science, Dec 8, 246(4935): 1300-1303 
Moberg, K., Starz, M.A., Lees, J.A. (1996). E2F-4 switches from p130 to p107 and pRb in response to 
cell cycle reentry. Mol Cell Biol, Apr 16(4): 1436-1449. 
Moller MB (2000). P27 in cell cycle control and cancer. Leukemia and Lymphoma, Sep, 39(1-2): 19-
27. 
Møller GM, Frost V, Melo JV, Chantry A. (2007). Upregulation of the TGFbeta signalling 
pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic 
myeloid leukaemia. FEBS Lett,  Apr 3, 581(7):1329-1334.  
Morita, N., Yamamoto, M., Tanizawa, T. (2003). Correlation of c-kit expression and cell cycle 
regulation by transforming growth factor-beta in CD34+ CD38- human bone marrow cells. 
Eur J Haematol, Nov, 71(5), 351-358.  
Mulligan, G.J., Wong, J., Jacks, T. (1998). p130 is dispensable in peripheral T lymphocytes: evidence 
for functional compensation by p107 and pRB. Mol Cell Biol, Jan, 18(1), 206-220. 
Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. 
(2001). Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse 
mammary gland morphogenesis and function. J Cell Biol. May 28, 153(5):917-932.  
Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, 
Hirao A. (2010). TGF-beta-FOXO signalling maintains leukaemia-initiating cells in 
chronic myeloid leukaemia. Nature,  Feb 4, 463(7281):676-680. 
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, 
Nakayama K. (1996) Mice lacking p27(Kip1) display increased body size, multiple 
organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, May 31, 85(5):707-
720.  
Okabe-Kado J, Honma Y, Hayashi M, Hozumi M. (1989). Inhibitory action of transforming 
growth factor-beta on induction of differentiation of myeloid leukemia cells. Jpn J 
Cancer Res. Mar, 80(3):228-232.  
Olsen AL, Stachura DL, Weiss MJ. (2006). Designer blood: creating hematopoietic lineages 
from embryonic stem cells. Blood; Feb 15, 107(4):1265-1275.  
Otten J, Schmitz L, Vettorazzi E, Schultze A, Marx AH, Simon R, Krauter J, Loges S, Sauter 
G, Bokemeyer C, Fiedler W. (2011). Expression of TGF-ǃ receptor ALK-5 has a 
negative impact on outcome of patients with acute myeloid leukemia. Leukemia. 
Feb;25(2):375-379. 
Ottmann, O.G. & Pelus, L.M. (1991). Differential proliferative effects of transforming growth 
factor-ǃ on human hematopoietic progenitor cells. J Immunol, Apr 15, 140(8), 2661-
2665.  
Park C, Afrikanova I, Chung YS, Zhang WJ, Arentson E, Fong Gh G, Rosendahl A, Choi K. 
(2004). A hierarchical order of factors in the generation of FLK1- and SCL-
expressing hematopoietic and endothelial progenitors from embryonic stem cells. 
Development, Jun, 131(11):2749-2762.  
Piedfer M, Dauzonne D, Tang R, N'guyen J, Billard C, Bauvois B. Aminopeptidase-N/CD13 
is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011 May 
12 (ahead of print).  
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
212 
Qin, X-Q., Livingston, D.M., Ewen, M., Sellers, W.R., Arany, Z., Kaelin, W.G. Jr. (1995). The 
transcription factor E2F1 is a downstream target of Rb action. Mol Cell Biol, Feb, 
15(2), 742-755.  
Quentmeier H, MacLeod RAF, Zaborski M and Drexler HG (2006) JAK2 V617F tyrosine 
kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia,  
Mar, 20(3) 471–476. 
Quentmeier H, Reinhardt J, Zaborski M and Drexler HG (2003). FLT3 mutations in acute 
myeloid leukemia cell lines. Leukemia, Jan,  17(1), 120–124. 
Rayman, J.B., Takahashi, Y., Indjeian, V.B., Dannenberg, J.H., Catchpoles, S., Watson, R.J., te 
Riele, H., Dynlacht, B.D. (2002). E2F mediates cell cycle-dependent transcriptional 
repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. 
Genes Dev, 16(8), 933-947. 
Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. (2002). E2F 
integrates cell cycle progression with DNA repair, replication, and G(2)/M 
checkpoints. Genes Dev. Jan 15, 16(2):245-56.  
Reynisdottir, I. & Massague, J. (1997).The subcellular locations of p15ink4b and p27kip1 
coordinate their inhibitory interactions with Cdk4 and cdk2. Genes Dev, Feb 15, 
11(4): 492-503. 
Rivard N, L'Allemain G, Bartek J, Pouysségur J. (1996). Abrogation of p27Kip1 by cDNA 
antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem. Aug 2, 
271(31):18337-18341.  
Rooke HM, Vitas MR, Crosier PS, Crosier KE. (1999). The TGF-beta type II receptor in 
chronic myeloid leukemia: analysis of microsatellite regions and gene expression. 
Leukemia. Apr, 13(4):535-541. 
Rosas M, Birkenkamp KU, Lammers JW, Koenderman L, Coffer PJ. (2005). Cytokine 
mediated suppression of TF-1 apoptosis requires PI3K activation and inhibition of 
Bim expression. FEBS Lett. Jan 3, 579(1):191-198. 
Rowell EA, Walsh MC, Wells AD. (2005). Opposing Roles for the Cyclin-Dependent Kinase 
Inhibitor p27kip1 in the Control of CD4+ T Cell Proliferation and Effector Function. 
The Journal of Immunology, Mar 15, 174(6): 3359-3368.  
Ruscetti, F.W., Akel, S., Bartelmez, S.H. (2005). Autocrine transforming growth factor-beta 
regulation of hematopoiesis: many outcomes that depend on the context. Oncogene, 
Aug 29, 24(37): 5751-5763.  
Russo AA, Jeffrey PD, Patten AK, Massagué J, Pavletich NP. (1996). Crystal structure of the 
p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. 
Nature. Jul 25, 382(6589):325-331.  
Sahin F and Sladek TL. (2010a). E2F-1 binding affinity for pRb is not the only determinant of 
the E2F-1 activity. , Jul 4, 6(4):382-395.  
Sahin F and Sladek TL. (2010b). E2F-1 has dual roles depending on the cell cycle. Int J Biol 
Sci. Mar 3, 6(2):116-128.  
Scandura JM, Boccuni P, Massagué J, Nimer SD (2004). Transforming growth factor beta-
induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-
regulation. Proc Natl Acad Sci U S A. Oct 19, 101(42):15231-15236.  
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
213 
Schwarz, J.K., Devoto, S.H., Smith, E.J., Chellappan, S.P., Jakoi, L., Nevins, J.R. (1993). 
Interactions of the p107 and Rb proteins with E2F during the cell proliferation 
response. EMBO J, Mar, 12(3): 1013-1020. 
Shirodkar, S., Ewen, M., DeCaprio, J.A., Morgan, J., Livingston, D.M., Chittenden, T. (1992). 
The transcription factor E2F interacts with the retinoblastoma product and a p107-
cyclin A complex in a cell cycle-regulated manner. Cell, Jan 10, 68(1): 157-166. 
Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M Allen R, Sidman C, Proetzel 
G, Calvin D,  Annunziata N,  Doetschman T (1992). Targeted disruption of the 
mouse transforming growth factor-b1 gene results in multifocal inflammatory 
disease. Nature, Oct 22, 359(6397): 693–699. 
Sing, G.K., Keller, J.R., Ellingsworth, L.R., Ruscetti, F.W. (1988). Transforming growth factor-
ǃ selectively inhibits normal and leukemic human bone marrow cell growth in 
vitro. Blood, Nov, 72(5): 1504-1511. 
Sitnicka, E., Ruscetti, F.W., Priestley, G.V., Wolf, N.S., Bartelmez, S.H. (1996) Transforming 
growth factor 1 directly and reversibly inhibits the initial cell divisions of long-
term repopulating hematopoietic stem cells. Blood, Jul 1, 88(1): 82-88 
Snoeck, H-W., Weekx, S., Moulijn, A., Lardon, F., Lenjou, M., Nys, F., Van Ranst, P.C.F., Van 
Bockstaele, D.R., Berneman, Z.N. (1996). Tumor necrosis factor ǂis a potent 
synergistic factor for the proliferation of primitive human hematopoietic progenitor 
cells and induces resistance to transforming growth factor ǃ but not to interferon Ǆ. 
J Exp Med, Feb 1, 183(2): 705-710. 
Sun H, Wang Y, Chinnam M, Zhang X, Hayward SW, Foster BA, Nikitin AY, Wills M, 
Goodrich DW. (2011) E2f binding-deficient Rb1 protein suppresses prostate tumor 
progression in vivo. Proc Natl Acad Sci U S A,  Jan 11, 108(2):704-709. 
Sundstrom C, Nilsson K. (1976). Establishment and characterization of a human histiocytic 
lymphoma cell line (U-937). Int J Cancer,  May 15, 17(5): 565-77. 
Suryadinata R, Sadowski M, Steel R, Sarcevic B (2011). Cyclin-dependent kinase-mediated 
phosphorylation of RBP1 and pRb promotes their dissociation to mediate release of 
the SAP30·mSin3·HDAC transcriptional repressor complex. J Biol Chem. Feb 
18;286(7):5108-5118. 
Takahashi, Y., Rayman, J.B., Dynlacht, B.D. (2000). Analysis of promoter binding by the E2F 
and pRB families in vivo: distinct E2F proteins mediate activation and repression. 
Genes Dev, Apr 1, 14(7), 804-816.  
Takaki T, Fukasawa K, Suzuki-Takahashi I, Hirai H. (2004). Cdk-mediated phosphorylation 
of pRB regulates HDAC binding in vitro. Biochem Biophys Res Commun. Mar 26, 
316(1):252-5. 
Tessier, N. & Hoang, T. (1988). Transforming growth factor beta inhibits the proliferation of 
the blast cells of acute myeloblastic leukemia. Blood, Jul, 72(1): 159-164 
Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell, May 5, 81(3): 323-
330. 
Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. (2000). Target gene specificity of E2F and 
pocket protein family members in living cells , Aug, 20(16):5797-5807. 
Wu, L., Timmers, C., Maiti, B., Saabedra, H.I., Sang, L., Chong, G.T., Nuckolls, F., Giangrande, P., 
Wright, F.A., Field, S.J., Greenberg, M.E., Orkin, S., Nevins, J.R., Robinson, M.L., Leone, 
G. (2001). The E2F1-3 transcription factors are essential for cellular proliferation. Nature, 
Nov 22, 414(6862): 457-462. 
www.intechopen.com
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
214 
Xu YZ, Thuraisingam T, Marino R, Radzioch D. (2011). Recruitment of SWI/SNF Complex 
Is Required for Transcriptional Activation of the SLC11A1 Gene during 
Macrophage Differentiation of HL-60 Cells. J Biol Chem,  Apr 15, 286(15):12839-
12849. 
Zhang H, Hannon GJ, Beach D (1994). p21-containing cyclin kinases exist in both active and 
inactive states. Genes Dev. Aug 1, 8(15):1750-1758. 
www.intechopen.com
Myeloid Leukemia - Basic Mechanisms of Leukemogenesis
Edited by Dr Steffen Koschmieder
ISBN 978-953-307-789-5
Hard cover, 484 pages
Publisher InTech
Published online 14, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The current book comprises a series of chapters from experts in the field of myeloid cell biology and myeloid
leukemia pathogenesis. It is meant to provide reviews about current knowledge in the area of basic science of
acute (AML) and chronic myeloid leukemia (CML) as well as original publications covering specific aspects of
these important diseases. Covering the specifics of leukemia biology and pathogenesis by authors from
different parts of the World, including America, Europe, Africa, and Asia, this book provides a colorful view on
research activities in this field around the globe.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Xiao Tang Hu (2011). Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells,
Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Dr Steffen Koschmieder (Ed.), ISBN: 978-953-
307-789-5, InTech, Available from: http://www.intechopen.com/books/myeloid-leukemia-basic-mechanisms-of-
leukemogenesis/distinct-inhibitory-effect-of-tgf-on-the-growth-of-human-myeloid-leukemia-cells
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
